TEVA rises 12.9% in a month as investors react to mixed first-quarter results, cost-cutting plans and growing momentum in branded and biosimilar drug sales.

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab ...

Teva’s plan (PDF) to reach $5 billion in 2030 innovative drug sales places the greatest emphasis on Austedo, which the company foresees hitting at least $2.5 billion in 2027 before reaching a ...

Teva Investor Relations Inquiries: TevaIR@Tevapharm.com The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties.

Teva employees in the USA Improving access to medicines and healthcare requires a continued effort to develop new evidence-based solutions that address unmet needs. We engage in scientific ...

Potential Positives. Teva Pharmaceuticals highlights a critical gap in the diagnosis and treatment of tardive dyskinesia (TD) among residents in long-term care facilities, showcasing their ...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE therapy in Phase 1 for the treatment of various forms of cancer, including melanoma; Fosun Pharma-Teva collaboration agreement established ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone.

A high-level overview of Teva Pharmaceutical Industries Limited (TEVA) stock. View (TEVA) real-time stock price, chart, news, analysis, analyst reviews and more.

Now, the FDA has said it will carry out a speedy review of a Teva medicine that it hopes can change that. The US regulator has awarded fast-track status for TEV-53408, ...

Prestige Biopharma announced on the 26th that it has signed a sales and supply agreement for the biosimilar 'Tuznue' (ingredient name trastuzumab) with Teva Pharmaceutical Industries' subsidiary ...